A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy

por Kuang, Zhihui, Li, Li, Zhang, Pan, Chen, Bingliang, Wu, Min, Ni, Haiqing, Yi, Shuai, Zou, Jia, Liu, Junjian
Publicado 2020

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit

por Wang, Jie, Fei, Keke, Jing, Hua, Wu, Zhihai, Wu, Weiwei, Zhou, Shuaixiang, Ni, Haiqing, Chen, Bingliang, Xiong, Yan, Liu, Yanpeng, Peng, Bo, Yu, Dechao, Jiang, Haiping, Liu, Junjian
Publicado 2019

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity

por Jiang, Haiping, Ni, Haiqing, Zhang, Pan, Guo, Xiaoli, Wu, Min, Shen, Haoran, Wang, Jie, Wu, Weiwei, Wu, Zhihai, Ding, Jiazheng, Tang, Rong, Zhou, Shuaixiang, Chen, Bingliang, Yu, Michael, Jing, Hua, Liu, Junjian
Publicado 2021